



NEWS RELEASE

# Castle Biosciences to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

11/10/2021

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to inform disease management decisions and improve patient outcomes, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Thursday, Nov. 18, 2021, at 9:30 a.m. Eastern time.

Live audio webcasts of the company's presentations will be available by visiting Castle Biosciences' website at <https://ir.castlebiosciences.com/events-presentations/default.aspx>. Replays of the webcasts will be available for two weeks following the conclusion of the live broadcasts.

## About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage diagnostics company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx® -CMSeq), cutaneous squamous cell carcinoma (DecisionDx®-SCC), suspicious pigmented lesions (myPath® Melanoma and DecisionDx® DiffDx™-Melanoma) and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq). For more information about Castle's gene expression profile tests, visit [www.CastleTestInfo.com](http://www.CastleTestInfo.com).

Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate to severe psoriasis, atopic dermatitis and related conditions. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix.

For more information, visit [www.CastleBiosciences.com](http://www.CastleBiosciences.com).

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

### Investor Contact:

Camilla Zuckero

832-835-5158

[czuckero@castlebiosciences.com](mailto:czuckero@castlebiosciences.com)

### Media Contact:

Allison Marshall

[amarshall@castlebiosciences.com](mailto:amarshall@castlebiosciences.com)

Source: Castle Biosciences, Inc.